Qiming Venture Partners Leads USD22m Series A+ for China’s GluBio Therapeutics

Source(s):  PR Newswire (GluBio Therapeutics)

Qiming Venture Partners led a USD22m Series A extension round for GluBio Therapeutics, a US- and China-based biotech focused on developing targeted protein degradation (TPD) drugs, with follow-on from Lilly Asia Ventures and Kaitai Capital. Read more